Md. Code, Health-Gen. §§ 2-801 through 2-803: Prohibition Against Price Gouging for Essential Off-Patent or Generic Drugs – Maryland

Status: Enacted
Year Enacted: 2017
File: Download

A manufacturer or wholesale distributor may not engage in price gouging in the sale of an essential off-patent or generic drug. It is not a violation of subsection (a) of this section for a wholesale distributor to increase the price of an essential off-patent or generic drug if the price increase is directly attributable to additional costs for the drug imposed on the wholesale distributor by the manufacturer of the drug.


Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found